New chemo combo shows promise for Hard-to-Treat stomach and esophageal cancers
NCT ID NCT05332002
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing a rotating schedule of two chemotherapy regimens (FOLFOX and FOLFIRI), with or without the immunotherapy nivolumab, in 38 people with advanced HER2-negative gastric or esophageal cancer. The goal is to see if this approach improves tumor shrinkage and survival. Participants must not have had prior chemotherapy for their advanced cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Alternating chemotherapy (FOLFOX and FOLFIRI) with or without nivolumab
- What this could lead to
- If successful, this could offer a new chemotherapy schedule that improves response rates and survival for people with advanced gastroesophageal cancer.
- What could go wrong
- This is a small, early-phase trial with only 38 participants. The treatment may not work better than existing options and could cause significant side effects from the chemotherapy combination.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTROESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
RWJBarnabas Health - Monmouth Medical Center
RECRUITINGLong Branch, New Jersey, 07740, United States
Contact
-
RWJBarnabas Health - Monmouth Medical Center Southern Campus
RECRUITINGLakewood, New Jersey, 08701, United States
Contact
-
RWJBarnabas Health - Newark Beth Israel Medical Center
RECRUITINGNewark, New Jersey, 07112, United States
Contact
-
RWJBarnabas Health - Robert Wood Johnson University Hospital
RECRUITINGHamilton, New Jersey, 08690, United States
Contact
-
RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset
RECRUITINGNew Brunswick, New Jersey, 08903, United States
Contact
-
Rutgers Cancer Institute of New Jersey
RECRUITINGNew Brunswick, New Jersey, 08903, United States
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.